Company Overview

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines using artificial intelligence–driven drug discovery. The company operates primarily in the neuroscience and immuno-oncology industries, applying advanced analytics to identify new therapeutic uses for existing molecules. Its business model emphasizes accelerated development timelines and reduced clinical risk by leveraging established pharmacological compounds.

The company’s primary revenue driver is IGALMI® (dexmedetomidine) sublingual film, an FDA-approved treatment for acute agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel Therapeutics evolved from BioXcel LLC, a privately held AI-focused drug discovery company, and was incorporated as a public entity in 2017 before completing its initial public offering in 2018. Since then, it has transitioned from a pure clinical-stage company to one with a commercial product in the U.S. market.

Business Operations

BioXcel Therapeutics operates through two core business segments: Neuroscience and Immuno-Oncology. The Neuroscience segment is the company’s most advanced and commercially active area, anchored by IGALMI®, which is marketed in the United States through a specialty sales force targeting hospitals and emergency care settings. Revenue is primarily generated from product sales and, to a lesser extent, collaboration-related income.

The Immuno-Oncology segment focuses on the development of investigational therapies designed to modulate the immune system to improve cancer outcomes. The company utilizes proprietary AI and machine-learning platforms licensed from BioXcel LLC to identify candidate molecules. Operations are primarily U.S.-based, with clinical trials conducted domestically and selectively internationally through contract research organizations.

Strategic Position & Investments

BioXcel Therapeutics’ strategy centers on expanding the commercial reach of IGALMI® while advancing its pipeline through additional clinical indications and next-generation formulations. Growth initiatives include increasing penetration in emergency and inpatient psychiatric settings and pursuing label expansions for neurological and psychiatric disorders characterized by agitation.

The company has made targeted investments in clinical development rather than large-scale acquisitions, reflecting its capital-efficient model. Its pipeline includes late- and mid-stage assets in neuroscience and early- to mid-stage programs in immuno-oncology, supported by its AI-enabled discovery approach. Strategic collaborations are primarily centered on technology access and clinical execution rather than equity-based joint ventures.

Geographic Footprint

BioXcel Therapeutics is headquartered in New Haven, Connecticut, with its primary commercial and clinical operations concentrated in the United States. The company’s approved product is currently marketed only in the U.S., which represents its core revenue-generating region.

International exposure is limited but present through global clinical trial sites and regulatory planning for potential future market expansion. While the company does not maintain significant physical operations outside North America, its strategic outlook includes selective international development opportunities depending on clinical and regulatory outcomes.

Leadership & Governance

BioXcel Therapeutics is led by a management team with experience across biotechnology, pharmaceuticals, and data-driven drug development. The leadership emphasizes disciplined capital allocation, accelerated clinical development, and the integration of artificial intelligence into traditional drug development frameworks.

Key executives include:

• Vimal Mehta – Founder, Chief Executive Officer, and Chairman
• Nitin Aggarwal, MD, MBA – Chief Medical Officer
• Chief Financial Officer – Data inconclusive based on available public sources